D. Boral Capital reiterated their buy rating on shares of VolitionRx (NYSE:VNRX - Free Report) in a research note published on Monday morning,Benzinga reports. D. Boral Capital currently has a $5.00 price objective on the stock.
Separately, StockNews.com assumed coverage on shares of VolitionRx in a report on Friday, March 28th. They issued a "sell" rating on the stock.
Check Out Our Latest Analysis on VolitionRx
VolitionRx Stock Down 7.5 %
NYSE VNRX traded down $0.04 during trading hours on Monday, hitting $0.52. 72,732 shares of the company were exchanged, compared to its average volume of 176,444. The firm has a market cap of $47.82 million, a price-to-earnings ratio of -1.43 and a beta of 1.09. The company has a 50 day moving average of $0.58 and a two-hundred day moving average of $0.63. VolitionRx has a 52-week low of $0.43 and a 52-week high of $1.02.
Insider Buying and Selling at VolitionRx
In other VolitionRx news, CEO Cameron John Reynolds purchased 181,818 shares of the stock in a transaction that occurred on Wednesday, March 26th. The stock was purchased at an average cost of $0.55 per share, with a total value of $99,999.90. Following the completion of the acquisition, the chief executive officer now directly owns 2,299,222 shares of the company's stock, valued at $1,264,572.10. This trade represents a 8.59 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 12.80% of the stock is owned by insiders.
Institutional Trading of VolitionRx
Several institutional investors have recently modified their holdings of VNRX. Geode Capital Management LLC grew its position in shares of VolitionRx by 15.1% in the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company's stock valued at $439,000 after buying an additional 95,900 shares during the last quarter. Millennium Management LLC acquired a new position in VolitionRx in the fourth quarter valued at $36,000. Northern Trust Corp grew its holdings in shares of VolitionRx by 32.0% during the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company's stock worth $71,000 after purchasing an additional 28,579 shares during the last quarter. Lagoda Investment Management L.P. increased its position in shares of VolitionRx by 24.3% during the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company's stock worth $4,546,000 after purchasing an additional 1,481,000 shares in the last quarter. Finally, Two Sigma Securities LLC purchased a new stake in shares of VolitionRx in the 4th quarter valued at about $29,000. Hedge funds and other institutional investors own 8.09% of the company's stock.
About VolitionRx
(
Get Free Report)
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
See Also
Before you consider VolitionRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and VolitionRx wasn't on the list.
While VolitionRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
